Sign In
Step 1
Unite with Fellow Investors
Step 2
Choose the Best Attorney
Step 3
Provide Documents
Step 4
Follow Case Progress
Step 5
Get Payout
EW.US
id: 1370

Edwards Lifesciences (EW) Misleading Growth Projections Case

C.D. California
Court
8:24-cv-02221
Case number
02/06/2024
Class period Start
07/24/2024
Class period End
12/13/2024
Lead Plaintiff motion deadline
  • $EW stockholders filed a claim against Edwards Lifesciences for misleading them about the growth prospects of its TAVR platform.
  • After the financial results on July 24, 2024, $EW dropped by over 31%.
  • $EW investors can join this case to be notified about potential recovery.
Case Details:

On July 24, 2024, Edwards Lifesciences reported weaker-than-expected Q2 financial results, especially for its key product, the Transcatheter Aortic Valve Replacement (TAVR) platform.

Previously, Edwards made optimistic predictions, saying there was a large, under-treated population that would boost demand for TAVR. However, the company overestimated the actual demand for these procedures.

Edwards also didn’t disclose that newer heart treatments, including its own TMTT therapies, affected hospital workflows. Hospitals began prioritizing these newer treatments over TAVR, which slowed its growth.

Despite knowing these challenges, Edwards continued to assure investors that TAVR would grow strongly. The company also made three acquisitions during Q2, hinting at underlying issues with TAVR growth.

On July 24, 2024, Edwards reduced its full-year revenue forecast for TAVR, citing slower-than-expected demand and increased competition from newer treatments.

Following this news, $EW dropped over 31%.

Based on these events, $EW investors filed a claim against Edwards Lifesciences, accusing them of the following:
  • The company misled investors about TAVR’s growth potential.
  • It overstated confidence in capturing a large, under-treated patient population.
  • It failed to disclose the impact of competition from newer therapies on TAVR growth.
Investors believe Edwards Lifesciences misled them by overstating TAVR growth prospects and underestimating the competitive challenges.
Case Status
Lead Plaintiff Appointed
Alleged Offence
Misleading Statements
Financial Misrepresentation
Failure to Disclose
Suspected Party
Management
Security Type
Stocks
Trade Direction
Long
Shock Event Date
07/24/2024
Filing date
10/14/2024
Lead Plaintiff Deadline
12/13/2024
Collecting participants…

Edwards Lifesciences Corp

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers tra...

    Ticker
    EW.US
    ISIN
    US28176E1082
    CIK
    1099800
    Sector
    Healthcare
    Industry
    Medical Devices
    Country
    USA
    Address
    One Edwards Way, Irvine, CA, United States, 92614